论文部分内容阅读
目的:探讨腹腔镜胃癌根治术联合生物免疫疗法对患者免疫功能及生活质量的影响研究。方法:选取2013年1月—2014年2月行腹腔镜胃癌根治术治疗并完成辅助治疗的I~III期胃癌患者64例,根据患者采取的辅助治疗方案分为免疫组(n=36)和化疗组(n=28),免疫组患者术后采用生物免疫疗法治疗,化疗组患者术后采用化疗治疗。观察两组患者治疗后的临床疗效,分别于辅助治疗前后检测两组患者血清中CD3+、CD4+、CD4+/CD8+、NK细胞水平等免疫功能指标,并采取生活质量核心量表(QLQ-C30)评价两组患者辅助治疗结束后3个月的生活质量并进行比较。结果:免疫组患者辅助治疗开始后3周的总有效率为75.00%,明显高于化疗组患者的67.86%(P<0.05);免疫组患者在生物免疫治疗后血清中CD3+、CD4+、CD4+/CD8+、NK细胞比率较治疗前明显升高(P<0.05),且明显高于化疗组(P<0.05);免疫组和化疗组总体生活质量评分分别为(76.37±17.43)分和(70.14±15.28)分,组间差异有统计学意义(P<0.05);免疫组患者在情感功能、恶心呕吐、疼痛、食欲丧失、腹泻方面优于化疗组,差异军有统计学意义(P<0.05)。结论:腹腔镜胃癌根治术后给予生物免疫疗法,可有效增强患者术后免疫功能,整体提高患者术后生活质量。
Objective: To investigate the effect of laparoscopic radical gastrectomy combined with bio-immunotherapy on immune function and quality of life of patients. Methods: Sixty-four patients with stage I-III gastric cancer undergoing laparoscopic radical gastrectomy and adjuvant therapy from January 2013 to February 2014 were divided into three groups according to the adjuvant therapy: n = 36 In the chemotherapy group (n = 28), patients in the immunized group were treated with bioimmunotherapy postoperatively, and patients in the chemotherapy group were treated with chemotherapy. The clinical efficacy of the two groups of patients was observed. The serum levels of CD3 +, CD4 +, CD4 + / CD8 + and NK cells in the two groups were detected before and after adjuvant therapy. The QOL of QLQ-C30 The quality of life at 3 months after the end of adjuvant therapy in both groups was compared and compared. Results: The total effective rate was 75.00% 3 weeks after adjuvant therapy in the immunized group, which was significantly higher than 67.86% (P <0.05) in the chemotherapy group. In the immunized group, the serum CD3 +, CD4 +, CD4 + / CD8 + (P <0.05), and significantly higher than those in chemotherapy group (P <0.05). The overall quality of life scores of immunized group and chemotherapy group were (76.37 ± 17.43) and (70.14 ± (P <0.05). The immunized group was better than chemotherapy group in emotional function, nausea and vomiting, pain, loss of appetite and diarrhea, the difference was statistically significant (P <0.05) . Conclusions: Bio-immunotherapy after radical operation of laparoscopic gastric cancer can effectively enhance the postoperative immune function and improve overall postoperative quality of life.